Granahan Investment Management LLC Buys 427,719 Shares of Cellebrite DI Ltd. $CLBT

Granahan Investment Management LLC increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,057,018 shares of the company’s stock after acquiring an additional 427,719 shares during the period. Cellebrite DI makes up 2.4% of Granahan Investment Management LLC’s investment portfolio, making the stock its 8th largest position. Granahan Investment Management LLC owned about 1.28% of Cellebrite DI worth $55,118,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Norwood Investment Partners LP acquired a new stake in shares of Cellebrite DI in the third quarter worth approximately $4,274,000. Wisconsin Capital Management LLC acquired a new stake in shares of Cellebrite DI in the third quarter worth approximately $1,649,000. Portolan Capital Management LLC boosted its position in shares of Cellebrite DI by 139.1% in the third quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after acquiring an additional 1,407,818 shares during the last quarter. TD Asset Management Inc boosted its position in shares of Cellebrite DI by 52.8% in the third quarter. TD Asset Management Inc now owns 324,241 shares of the company’s stock worth $6,008,000 after acquiring an additional 112,005 shares during the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in shares of Cellebrite DI in the third quarter worth approximately $11,406,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 13,269 shares of company stock valued at $169,592 in the last 90 days. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $12.81 on Wednesday. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The company’s 50 day moving average price is $13.19 and its 200 day moving average price is $14.98. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 1.62 and a beta of 1.17.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson assumed coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC decreased their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.